Ionis Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax
Ionis Pharmaceuticals, Inc. (IONS) reported Other Comprehensive Income (Loss), Net of Tax of -$24.81 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-02-22
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2018-12-31 was $516.00K.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2018-09-30 was $105.00K, a 39.31% decline year-over-year.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2018-06-30 was $600.00K, a 581.82% increase year-over-year.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2018-03-31 was -$1.48M.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$24.81M.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2021 was -$11.60M, a 374.88% decline from fiscal 2020.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2020 was $4.22M, a 37.27% decline from fiscal 2019.
- Ionis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2019 was $6.73M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|---|---|
| 2022-12-31 | -$24.81M 10-K · filed 2023-02-22 | |||||
| 2021-12-31 | -$11.60M 10-K · filed 2023-02-22 | |||||
| 2020-12-31 | $4.22M 10-K · filed 2023-02-22 | |||||
| 2019-12-31 | $6.73M 10-K · filed 2022-02-25 | |||||
| 2018-12-31 | $516.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $621.00K derived: sum of 2 quarters · filed 2021-02-24 | $1.22M derived: sum of 3 quarters · filed 2021-02-24 | -$257.00K 10-K · filed 2021-02-24 | ||
| 2018-09-30 | $105.00K 10-Q · filed 2018-11-06 | $705.00K derived: sum of 2 quarters · filed 2018-11-06 | -$773.00K 10-Q · filed 2018-11-06 | -$2.33M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | $600.00K 10-Q · filed 2018-08-07 | -$875.00K 10-Q · filed 2018-08-07 | -$2.44M derived: sum of 3 quarters · filed 2020-03-02 | -$2.26M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | -$1.48M 10-Q · filed 2018-05-07 | -$3.04M derived: sum of 2 quarters · filed 2020-03-02 | -$2.86M derived: sum of 3 quarters · filed 2020-03-02 | -$2.77M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2017-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$1.39M derived: sum of 2 quarters · filed 2020-03-02 | -$1.30M derived: sum of 3 quarters · filed 2020-03-02 | -$1.40M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $173.00K 10-Q · filed 2018-11-06 | $229.00K 10-Q · filed 2017-11-07 | $261.00K derived: sum of 2 quarters · filed 2018-11-06 | $159.00K 10-Q · filed 2018-11-06 | $127.00K 10-Q · filed 2017-11-07 | -$3.70M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $88.00K 10-Q · filed 2018-08-07 | -$14.00K 10-Q · filed 2018-08-07 | -$3.87M derived: sum of 3 quarters · filed 2019-03-01 | -$3.52M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-03-31 | -$102.00K 10-Q · filed 2018-05-07 | -$3.96M derived: sum of 2 quarters · filed 2019-03-01 | -$3.61M derived: sum of 3 quarters · filed 2019-03-01 | |||
| 2016-12-31 | -$3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$3.50M derived: sum of 2 quarters · filed 2019-03-01 | -$16.79M 10-K · filed 2019-03-01 | |||
| 2016-09-30 | $355.00K 10-Q · filed 2017-11-07 | -$12.93M 10-Q · filed 2017-11-07 | ||||
| 2015-12-31 | -$53.31M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |